Drugs / Propiverine
Propiverine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00795925 | Oct 2004 → Dec 2005 | overactive bladder | APOGEPHA Arzneimittel GmbH | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01530620 | Dec 2004 → Jun 2005 | overactive bladder | APOGEPHA Arzneimittel GmbH | Completed | No outcome recorded |
| Phase 42 trials · 1 met primary | ||||||
| Phase 4 | NCT02294396 | Oct 2014 → Sep 2016 | overactive bladder | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT00903045 | Jan 2005 → Aug 2006 | overactive bladder | Samsung Medical Center | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT01942681 | Sep 2013 → Jun 2015 | female stress incontinence | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 3 | NCT01512004 Comparator | Jan 2010 | overactive bladder | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 3 | NCT00603343 Comparator | Jun 2004 → Sep 2006 | overactive bladder | APOGEPHA Arzneimittel GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00646880 Comparator | Mar → Aug 2003 | overactive bladder | Pfizer | Completed | No outcome recorded |
| — | NCT03844581 Comparator | Jan 2019 | interstitial cystitis | Cairo University | Completed | No outcome recorded |
| — | NCT03662893 Comparator | Jan 2015 → Dec 2017 | overactive bladder | Ankara Training and Research Hospital | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | propiverine | “Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)” NCT03662893 ↗9“propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)” NCT00603343 ↗ |
| Known as | Mictonetten | “Dose-Escalating Study of Propiverine Hydrochloride (Mictonetten®) in Children Suffering From Frequency-Urgency-Syndrome and Urinary Incontinence Indicative of Detrusor...” NCT00795925 ↗ |
| Known as | Propiverina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1078261 ↗ |
| Known as | propiverine hydrochloride | “The purpose of this Phase III study is to evaluate the efficacy and safety of Propiverine Hydrochloride Extended-Release Capsule in the treatment of overactive bladder in...” NCT01512004 ↗1“Drug: propiverine hydrochloride” NCT00795925 ↗ |
| Modality | Small molecule | — CHEMBL1078261 ↗ |
| Route | Oral | “30 mg/capsule; oral; once per day” NCT01512004 ↗ |